GLP-1 Diabetes Medications and Their Impact on Mental Health

Recent research published in *Lancet Psychiatry* indicates that GLP-1 receptor agonists, particularly semaglutide and liraglutide, may help mitigate the worsening of anxiety and depression in individuals with type 2 diabetes. Type 2 diabetes affects over 800 million people worldwide, and those with the condition are approximately twice as likely to experience depression compared to the general population. The study analyzed Swedish health records of nearly 95,000 patients diagnosed with anxiety or depression who were prescribed various diabetes medications from 2009 to 2022.

The Guardian

The findings revealed that semaglutide, the active ingredient in the diabetes medication Ozempic and the weight loss drug Wegovy, was associated with a 42% lower risk of worsening mental health. Liraglutide was linked to an 18% lower risk. Other GLP-1 drugs, such as exenatide and dulaglutide, did not demonstrate similar benefits. Specifically, semaglutide was correlated with a 44% reduction in the risk of worsening depression, a 38% reduction in anxiety, and a 47% reduction in worsening substance use disorder.

The Guardian

While the results are promising, experts urge caution regarding the interpretation of these findings. Prof. David Nutt, head of the neuropsychopharmacology unit at Imperial College London, emphasized that while better physical health can lead to improved mental health, it is unlikely that GLP-1 receptor agonists alone will serve as effective treatments for depression or anxiety. Similarly, Prof. Eduard Vieta from the University of Barcelona noted that while the findings suggest a potential role for these medications in preventing the deterioration of mental health, they should not be seen as direct evidence of therapeutic effects on anxiety or depression.

The Guardian

In addition to the mental health implications, a separate study highlighted potential risks associated with GLP-1 medications during pregnancy. This research examined Danish health registries and found that women who took semaglutide or liraglutide before knowing they were pregnant had an 84% higher relative risk of preterm birth compared to those who did not use these medications. The risk was 70% higher for those taking liraglutide. Specifically, semaglutide was associated with an 11% higher absolute risk of preterm birth, while liraglutide showed a 9% increased risk.

The Guardian

The research suggests that GLP-1 receptor agonists like semaglutide and liraglutide may offer dual benefits for individuals with type 2 diabetes by potentially reducing the risk of worsening mental health conditions. However, experts caution against viewing these medications as standalone treatments for anxiety and depression. Additionally, the findings regarding pregnancy risks necessitate careful consideration for women of childbearing age using these drugs. Further research is needed to fully understand the implications of GLP-1 medications on both mental health and pregnancy outcomes.

The Guardian